(Q43723222)

26 November 2017

Ribozyme targeting of HER-2 inhibits pancreatic cancer cell growth in vivo (English)

1 reference

26 November 2017

0 references

1 reference

1 reference

Thybusch-Bernhardt A

1

1 reference

26 November 2017

Aigner A

2

1 reference

26 November 2017

Beckmann S

3

1 reference

26 November 2017

Czubayko F

4

1 reference

26 November 2017

Juhl H

5

1 reference

26 November 2017

1 September 2001

1 reference

European Journal of Cancer

26 November 2017

1 reference

26 November 2017

37

1 reference

26 November 2017

13

1 reference

26 November 2017

1688-1694

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

26 November 2017

1 reference

7 January 2021

Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

Overexpression of HER2/neu oncogene in human pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

Molecular biology of breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

Ribozymes as human therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

Tight control of gene expression in mammalian cells by tetracycline-responsive promoters

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

The c-erb B-2 proto-oncogene in human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900181-2

7 January 2021

10.1016/S0959-8049(01)00181-2

Identifiers

DOI

1 reference

26 November 2017

1 reference